8-K: Tevogen Bio Holdings Inc. Increases Outstanding Shares with Significant Restricted Stock Grants, CEO Awarded 8 Million Shares

Tevogen Bio Holdings Inc. announced a substantial increase in its outstanding common stock to 193,693,433 shares following restricted stock grants, including 8 million shares to CEO Dr. Ryan Saadi with a seven-year vesting commencement.

Summary

• Tevogen Bio Holdings Inc. reported an increase in its outstanding common stock to 193,693,433 shares as of July 10, 2025.
• This increase is a result of restricted stock award grants approved by the Board of Directors on June 27, 2025.
• The grants include 8,000,000 shares of restricted stock awarded to the company's Chief Executive Officer and Chairperson, Dr. Ryan Saadi.
• Dr. Saadi's shares will vest in four equal annual installments, commencing on the seventh anniversary of the grant date.
• Shares granted to other recipients will vest in three equal annual installments, beginning on the fifth anniversary of the grant date.
• Vesting is contingent upon continuous service, with automatic full vesting upon termination due to death or disability.
• The restricted shares are subject to forfeiture and cannot be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered prior to vesting.

Sentiment

Score: 4

Explanation: While the grants serve as a long-term incentive and retention tool for key management, the immediate increase in outstanding shares and the significant potential future dilution from the 8,000,000 shares granted to the CEO are negative for existing shareholders. The very long vesting period for the CEO is a positive for long-term commitment but does not offset the immediate dilutive effect.

Positives

• The restricted stock grants, particularly to the CEO, serve as a long-term incentive and retention mechanism, aligning management's interests with long-term shareholder value.
• The very long vesting period for the CEO (starting 7 years after grant) indicates a strong commitment from Dr. Ryan Saadi to the company's long-term success.
• The grants are subject to continuous service, ensuring key personnel remain engaged with the company.

Negatives

• The issuance of 8,000,000 restricted shares, particularly to the CEO, contributes to an immediate increase in the number of outstanding shares, leading to dilution for existing shareholders.
• The total outstanding shares increased to 193,693,433, representing a significant base for future potential dilution as these restricted shares vest.

Risks

• Potential future dilution of existing shareholders as the restricted stock awards vest over time.
• The long vesting periods mean the full impact of these grants on outstanding shares will not be realized for several years, potentially creating uncertainty.
• The value of these awards to recipients is tied to the future stock price, which could create pressure for short-term gains if not managed properly.

Future Outlook

The restricted stock awards, particularly the long vesting periods (5 to 7 years for commencement of vesting), indicate a long-term strategic outlook for retaining key management and aligning their incentives with the company's sustained performance. The grants are designed to incentivize continuous service and long-term value creation.

Management Comments

• As a result of restricted stock award grants approved by the Board of Directors of Tevogen Bio Holdings Inc. (the Company) on June 27, 2025, including a grant of 8,000,000 shares of restricted stock to the Companys Chief Executive Officer and Chairperson, Dr. Ryan Saadi, the number of shares of the Companys common stock, par value $0.0001 per share, outstanding as of the date hereof is 193,693,433.
• The shares of restricted stock granted to Dr. Saadi will vest in four equal annual installments beginning on the seventh anniversary of the grant date and the shares of restricted stock granted to each other grantee will vest in three equal annual installments beginning on the fifth anniversary of the grant date, subject in each case to the applicable grantees continuous service with the Company through the vesting date, and provided that the shares will automatically vest in full in the event of termination due to death or disability.

Industry Context

Restricted stock awards are a common form of executive and employee compensation in the biotechnology and pharmaceutical industries, often used to attract and retain talent in a highly competitive sector. The long vesting periods observed here are typical for early-stage or growth companies aiming to secure long-term commitment from key scientific and executive leadership, especially given the extended timelines for drug development and regulatory approvals.

Comparison to Industry Standards

• The use of restricted stock awards is a standard practice for executive compensation in the biotech industry, aligning with common strategies for talent retention and long-term incentive.
• The vesting period for the CEO, commencing seven years after the grant date, is notably longer than typical annual or three-to-five-year vesting schedules often seen in more mature companies, suggesting a strong emphasis on very long-term commitment, which is not uncommon for biotech companies with long R&D cycles.
• While specific comparable companies are not mentioned, this structure is often seen in companies like Moderna or BioNTech during their earlier growth phases, where key scientific and executive talent are incentivized for multi-year drug development pipelines.

Corporate Governance

Related Party Transactions

• The grant of 8,000,000 shares of restricted stock to Dr. Ryan Saadi, the company's Chief Executive Officer and Chairperson, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Experience immediate dilution due to the increased number of outstanding shares and face potential future dilution as restricted shares vest.
• Employees (Grantees): Benefit from long-term equity incentives, aligning their financial interests with the company's performance and encouraging continuous service.
• Management (Dr. Ryan Saadi): Receives a significant long-term incentive, reinforcing commitment to the company's future.

Next Steps

• Continued service of grantees to meet vesting conditions.
• Annual vesting of restricted stock awards beginning on the fifth and seventh anniversaries of the grant date for different grantee groups.

Key Dates

Keywords

Tevogen Bio Holdings Inc., TVGN, SEC Filing, 8-K, Restricted Stock, Stock Awards, Executive Compensation, Dilution, Corporate Governance, Biotechnology, Pharmaceutical, Nasdaq, Common Stock, Warrants